Many readers may be interested in two expert interviews on the OncologySTAT web site with Dr. Mark Emberton (a member of the Scientific Advisory Board of The “New “Prostate Cancer InfoLink).
Dr. Emberton (who is based in London, England) has been a leader in the potential for application of focal therapy and active surveillance in the management of early stage prostate cancer over the past few years. To read the two interviews, you will need to “sign up” to become a member of OncologySTAT, but there is no charge and you do not have to get a barrage of daily e-mails.
In the first of the two interviews (“My approach to intervention for prostate cancer: treat the cancer, not the gland—Part I“), Dr. Emberton talks about the roles of targeted biopsies and MRI techniques to risk stratify men with prostate cancer into potential management categories.
In the second of the interviews (“My approach to intervention for prostate cancer: treat the cancer, not the gland—Part II“), Dr. Emberton concentrates on the appropriate selection of patients as candidates for focal therapy and how the community-based physicians can gain the essential skills necessary to administer the therapy effectively and safely.
Filed under: Diagnosis, Living with Prostate Cancer, Management, Risk, Treatment Tagged: | early, focal, stage, therapy
Search for new and
ongoing trials on the
CTAG PCa web site
Well, for patients this is welcome news. For most doctors too.